LR004
LR004 is an EGFR monoclonal antibody, with a Kd of 2.80×10-9 M against human EGFR. LR004 shows extremely weak inhibitory effect on the viability of EGFR-positive tumor cells in vitro, but inhibits the growth of EGFR-positive tumor xenografts as a single agent. LR004 is applicable to research related to advanced colorectal cancer, solid tumors, esophageal squamous cell carcinoma, epidermoid carcinoma, colon cancer and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform EGFR
More
Activité biologique
Human
LR004 (5.0 μg/mL) binds recombinant human EGFR antigen with moderate affinity, with a Kd of 2.80×10-9 M[1].
LR004 (0.023-50 μg/mL; 24 h initial incubation, followed by 96 h incubation with serum-containing medium) inhibits the proliferation of MDA-MB-468 human breast cancer cells with an EC50 of 2.278 μg/mL[1].
LR004 (0.001-1 μg·mL-1; 48 h) has weak in vitro cytotoxicity against human EGFR-positive tumor cells (KYSE520, KYSE150, A431, HCC827, NCI-H1975, A549, MDA-MB-468, MCF-7, AsPC-1) and EGFR-negative Karpas 299 cells, with IC50 values >6 nM or >60 nM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-468 human breast cancer cells
-
Concentration:0.023-50 μg/mL
-
Incubation Time:24 h (initial incubation); 96 h (incubation with serum-containing medium)
-
Result:Inhibited MDA-MB-468 cell proliferation with an EC50 of 2.278 μg/mL.
-
Cell Line:KYSE520, KYSE150, A431, HCC827, NCI-H1975, A549, MDA-MB-468, MCF-7, AsPC-1, Karpas 299
-
Concentration:0.001-1 μg·mL-1
-
Incubation Time:48 h
-
Result:Had a weak inhibitory effect on cell viability, with IC50 values >6 nM for KYSE520, KYSE150, A431, HCC827, NCI-H1975, A549, MDA-MB-468, MCF-7, and AsPC-1 cells, and IC50 >60 nM for Karpas 299 cells.
LR004 (15 mg/kg; i.v.; every 4 days; 6 total doses) exerts limited tumor growth suppression in A431 epidermoid carcinoma xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6-8 weeks old, 18-20 g, KYSE520 tumor cell xenograft)[2]
-
Dosage:15 mg/kg
-
Administration:i.v.; every 4 days; 4 total doses
-
Result:Achieved an average tumor volume of 1791 mm3 on day 44.
Induced a 13.8% tumor inhibition rate.
Showed no tumor regression.
Caused no body weight loss or mortality.
Detected no histopathological abnormalities in major organs.
-
Animal Model:BALB/c nude (female, 6-8 weeks old, 18-20 g, A431 tumor cell xenograft)[2]
-
Dosage:15 mg/kg
-
Administration:i.v.; every 4 days; 6 total doses
-
Result:Achieved an average tumor volume of 399 mm3 on day 60.
Exhibited limited therapeutic activity compared to LR004-VC-MMAE groups.
Detected no histopathological abnormalities in major organs.
P00533-1
EGFR
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[LR004]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Zheng Y, et al. Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody. Molecules. 2024;29(2):545. Published 2024 Jan 22. [Content Brief]
[2]. Hu XY, et al. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Mol Oncol. 2019;13(2):246-263. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LR004 Related Classifications
HY-P991969 Related Classifications
Powered by Bioz